Skip to Content
Merck

1672803

USP

Transplatin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

trans-Platinum(II)diammine dichloride, trans-Diamminedichloroplatinum(II), trans-Dichlorodiammineplatinum(II)

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

25 MG

CZK 30,900.00

CZK 30,900.00

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Linear Formula:
Pt(NH3)2Cl2
CAS Number:
14913-33-8
Molecular Weight:
300.05
NACRES:
NA.24
PubChem Substance ID:
329751363
UNSPSC Code:
41116107
MDL number:
MFCD00011623

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Transplatin, United States Pharmacopeia (USP) Reference Standard

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

SMILES string

N.N.Cl[Pt]Cl

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

grade

pharmaceutical primary standard

API family

cisplatin

manufacturer/tradename

USP

mp

340 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
BP544PHR32521134357
Transplatin United States Pharmacopeia (USP) Reference Standard

USP

1672803

Transplatin

Transplatin British Pharmacopoeia (BP) Reference Standard

BP544

Transplatin

Transplatin pharmaceutical secondary standard, certified reference material

Supelco

PHR3252

Transplatin

Cisplatin United States Pharmacopeia (USP) Reference Standard

USP

1134357

Cisplatin

grade

pharmaceutical primary standard

grade

-

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

manufacturer/tradename

USP

manufacturer/tradename

BP

manufacturer/tradename

-

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

application(s)

pharmaceutical

application(s)

pharmaceutical (small molecule)

format

neat

format

-

format

-

format

neat

API family

cisplatin

API family

cisplatin

API family

cisplatin

API family

cisplatin

mp

340 °C (dec.) (lit.)

mp

340 °C (dec.) (lit.)

mp

340 °C (dec.) (lit.)

mp

270 °C (lit.)

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

comparable product

Product No.
Description
Pricing

related product

Product No.
Description
Pricing

pictograms

Health hazardCorrosion
GHS08,GHS05

signalword

Danger

Hazard Classifications

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

Storage Class

13 - Non Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
Yuniardini S Wimardhani et al.
Journal of oral science, 56(2), 119-126 (2014-06-17)
Chitosan, a multipurpose biomaterial, has been shown to exert effects against several types of cancer including oral cancer. However, the mechanisms underlying the anticancer activities of chitosan on oral squamous cell carcinoma (SCC) cells remain largely unknown. The present study
Michelle X Liu et al.
Oncotarget, 5(4), 944-958 (2014-03-25)
Epithelial ovarian cancer is a highly lethal and aggressive gynecological malignancy. The high mortality rate is due in part to the fact that many advanced cancer patients become refractory to current chemotherapeutic agents, leading to tumor recurrence and death. However
Wei Qian et al.
Oncotarget, 5(12), 4180-4194 (2014-06-24)
Overcoming platinum drug resistance represents a major clinical challenge in cancer treatment. We discovered a novel drug combination using cisplatin and a class of thioquinazolinone derivatives including mdivi-1 (mitochondrial division inhibitor-1), that induces synergistic apoptosis in platinum resistant tumor cells
James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service